Table 2.
Biochemically Verified Abstinence Rates by Treatment Group
| Continuous Abstinence (2-week grace)1 % Abstinent (N) |
Continuous Abstinence (FDA)2 % Abstinent (N) |
Prolonged Abstinence3 % Abstinent (N) |
7-Day Point Prevalence4 % Abstinent (N) |
||
|---|---|---|---|---|---|
| End of Treatment5 | |||||
| Bupropion Group (B) | (N=102) | 36.3 (37) | 39.2 (40) | 46.1 (47) | 49.0 (50) |
| Placebo Group (P) | (N=106) | 17.0 (18) | 18.9 (20) | 26.4 (28) | 28.3 (30) |
| Varenicline Group (V) | (N=86) | 43.0 (37) | 47.7 (41) | 58.1 (50) | 58.1 (50) |
| OR (95% CI): B vs. P | 2.78 (1.46,5.32) | 2.77 (1.48,5.20) | 2.38 (1.33,4.25) | 2.44 (1.37,4.32) | |
| OR (95% CI): V vs. P | 3.69 (1.90,7.16) | 3.92 (2.06,7.47) | 3.87 (2.11,7.11) | 3.52 (1.93,6.42) | |
| OR (95% CI): V vs. B | 1.33 (0.74,2.39) | 1.41 (0.79,2.42) | 1.62 (0.91,2.90) | 1.44 (0.81,2.58) | |
| Wald Chi-Square for Group | χ2(2)= 15.87, p<.0004 | χ2(2)= 18.10, p<.0001 | χ2(2)= 19.55, p<.0001) | χ2(2)= 17.95, p<.0 | |
| 3 month Follow-up6 | |||||
| Bupropion Group | 35.3 (36) | 37.2 (38) | 41.2 (42) | 43.1 (44) | |
| Placebo Group | 16.0 (17) | 17.0 (18) | 25.5 (27) | 31.1 (33) | |
| Varenicline Group | 39.5 (34) | 43.0 (37) | 53.5 (46) | 58.1 (50) | |
| OR (95% CI): B vs. P | 2.86 (1.48,5.52) | 2.90 (1.52,5.54) | 2.05 (1.14,3.69) | 1.68 (0.95,2.96) | |
| OR (95% CI): V vs. P | 3.42 (1.74,6.72) | 3.69 (1.90,7.16) | 3.37 (1.83,6.18) | 3.07 (1.70,5.56) | |
| OR (95% CI): V vs. B | 1.20 (0.66,2.17) | 1.27 (0.71,2.28) | 1.64 (0.92,2.93) | 1.83 (1.02,3.27) | |
| Wald Chi-Square for Group | χ2(2)= 14.21, p<.0008 | χ2(2)= 16.22, p=.0003 | χ2(2)= 15.40, p<.0005 | χ2(2)= 13.73, p<.0 | |
| 6 month Follow-up7 | |||||
| Bupropion Group | 22.5 (23) | 22.5 (23) | 26.5 (27) | 28.4 (29) | |
| Placebo Group | 14.1 (15) | 14.1 (15) | 17.9 (19) | 23.6 (25) | |
| Varenicline Group | 27.9 (24) | 27.9 (24) | 38.4 (33) | 37.2 (32) | |
| OR (95% CI): B vs. P | 1.77 (0.86,3.62) | 1.77 (0.86,3.62) | 1.65 (0.85,3.20) | 1.29 (0.69,2.40) | |
| OR (95% CI): V vs. P | 2.35 (1.14,4.83) | 2.35 (1.14,4.83) | 2.85 (1.47,5.51) | 1.92 (1.03,3.59) | |
| OR (95% CI): V vs. B | 1.33 (0.69, 2.58) | 1.33 (0.68,2.58) | 1.73 (0.93,3.21) | 1.49 (0.81,2.76) | |
| Wald Chi-Square for Group | χ2(2)= 5.45, p<.06 | χ2(2)= 5.45, p<.07 | χ2(2)= 9.80, p<.008 | χ2(2)= 4.26, p<.12 | |
Continuous abstinence (2-week grace)-no smoking on any day beginning with the end of the Grace Period, defined as 2 weeks after Quit Day.
Continuous abstinence (FDA)-no smoking on any day beginning with the last 4 weeks of treatment, or week 8 of medication.
Prolonged abstinence-relapse is defined by smoking for 7 or more consecutive days or by smoking at least 1 cigarette over two consecutive weeks beginning with the end of the 2-week Grace period.
7-day point prevalence is defined as no smoking in the last seven days of the given time period.
Occurs 10 weeks post Quit Date and is the end of pharmacotherapy
Occurs 3 months post Quit Date or 2 weeks following the end of pharmacotherapy
Occurs 6 months post Quit Date or 14 weeks following the end of pharmacotherapy